Prevention of breast tumour development in vivo by downregulation of the p185neu receptor - PubMed (original) (raw)

Prevention of breast tumour development in vivo by downregulation of the p185neu receptor

M Katsumata et al. Nat Med. 1995 Jul.

Abstract

Certain strains of transgenic mice that express the rat neu oncogene (neuT) in mammary epithelial cells develop breast tumours at an average of 44 weeks of age. In this study, intraperitoneal injection of a monoclonal anti-receptor antibody specific for the rat neuT oncogene product dramatically affected tumour development in these transgenic mice in a dose-dependent manner. A significant proportion (50%) of mice, when injected with anti-receptor antibodies, did not develop tumours even after 90 weeks of age. The phosphotyrosine levels of the membrane fraction of breast tissues in the anti-receptor antibody-treated mice were almost completely abolished when a higher dose of antibodies was used. This study demonstrates, for the first time, that immunologic manipulation of an oncogene product can effectively prevent the development of tumours in a rodent transgenic model.

PubMed Disclaimer

Comment in

• A target for tumour-directed therapy.
  Hynes NE, Groner B. Hynes NE, et al. Nat Med. 1995 Jul;1(7):631. doi: 10.1038/nm0795-631. Nat Med. 1995. PMID: 7585140 No abstract available.

Similar articles

• A target for tumour-directed therapy.
  Hynes NE, Groner B. Hynes NE, et al. Nat Med. 1995 Jul;1(7):631. doi: 10.1038/nm0795-631. Nat Med. 1995. PMID: 7585140 No abstract available.
• Use of mouse mammary tumour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development.
  Jolicoeur P, Bouchard L, Guimond A, Ste-Marie M, Hanna Z, Dievart A. Jolicoeur P, et al. Biochem Soc Symp. 1998;63:159-65. Biochem Soc Symp. 1998. PMID: 9513720 Review.
• Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.
  Wels W, Groner B, Hynes NE. Wels W, et al. Curr Top Microbiol Immunol. 1996;213 ( Pt 3):113-28. doi: 10.1007/978-3-642-80071-9_8. Curr Top Microbiol Immunol. 1996. PMID: 8815001 Review. No abstract available.
• Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
  Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ. Esserman LJ, et al. Cancer Immunol Immunother. 1999 Feb;47(6):337-42. doi: 10.1007/s002620050539. Cancer Immunol Immunother. 1999. PMID: 10203064 Free PMC article.
• Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.
  Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Cipriani B, Forni G, Monaci P. Gallo P, et al. Int J Cancer. 2007 Feb 1;120(3):574-84. doi: 10.1002/ijc.22274. Int J Cancer. 2007. PMID: 17096348

Cited by

• Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis.
  Aricò E, Sestili P, Carpinelli G, Canese R, Cecchetti S, Schiavoni G, D'Urso MT, Belardelli F, Proietti E. Aricò E, et al. Oncotarget. 2016 Sep 13;7(37):59754-59765. doi: 10.18632/oncotarget.10880. Oncotarget. 2016. PMID: 27486759 Free PMC article.
• ErbB receptors: from oncogenes to targeted cancer therapies.
  Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. Zhang H, et al. J Clin Invest. 2007 Aug;117(8):2051-8. doi: 10.1172/JCI32278. J Clin Invest. 2007. PMID: 17671639 Free PMC article. Review.
• 2011: the immune hallmarks of cancer.
  Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. Cavallo F, et al. Cancer Immunol Immunother. 2011 Mar;60(3):319-26. doi: 10.1007/s00262-010-0968-0. Epub 2011 Jan 26. Cancer Immunol Immunother. 2011. PMID: 21267721 Free PMC article.
• Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury.
  Calvo M, Zhu N, Tsantoulas C, Ma Z, Grist J, Loeb JA, Bennett DL. Calvo M, et al. J Neurosci. 2010 Apr 14;30(15):5437-50. doi: 10.1523/JNEUROSCI.5169-09.2010. J Neurosci. 2010. PMID: 20392965 Free PMC article.
• Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers.
  Du T, Nagai Y, Xiao Y, Greene MI, Zhang H. Du T, et al. Exp Mol Pathol. 2013 Aug;95(1):38-45. doi: 10.1016/j.yexmp.2013.04.003. Epub 2013 May 2. Exp Mol Pathol. 2013. PMID: 23644046 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal